Relief Therapeutics Holding AG (RLFTF)

[mc67]

$RLFTF (related) DD by Serge on Yh0 - Just for information, for all new boardmembers. Aviptadil is not only targetting Covid 19

VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease
(“COPD”), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome.

NeuroRx intends to research the use of VIP in these and other conditions in the future.

VIP is also known to be active in the brain and NeuroRx plans to
explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases if an
appropriate mechanism of CNS delivery can be developed